NRSN News

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study